# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Eva Perón (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML025-SYN
- Date: 2026-08-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucía Barragán, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Review three months after treatment, with the PET-CT result. **S**

## History of present illness

Ms. Perón returns three and a half months after finishing treatment. Her PET-CT a week ago showed a complete metabolic response, with no uptake in the cervix, nodes or elsewhere, and Dr. Osei-Bonsu's examination last month found no tumor. The estradiol patch and progesterone stopped the hot flashes and night sweats within a few weeks. She uses the dilator three times a week; intercourse is comfortable with a lubricant. Her energy is nearly back, she has regained weight, and she is working full days again. She has had no bleeding, pelvic or back pain, or leg swelling. **S**

| Element | Detail |
|---|---|
| PET-CT | Complete metabolic response a week ago |
| Menopause care | Symptoms controlled on estradiol and progesterone |
| Dilator | Three times a week |
| Work | Full days again |
| Scores | PHQ-9 4; GAD-7 4; pain 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy nearly normal; weight regained; no night sweats |
| Gastrointestinal | Negative | Bowels normal; no rectal bleeding |
| Genitourinary | Negative | No bleeding or discharge; no urinary symptoms |
| Musculoskeletal | Negative | No back or pelvic pain; no leg swelling |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day **S**
- Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly **S**
- Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 52.4 kg; BMI 19.2 kg/m². All vital signs are synthetic.

Hemoglobin: 12.6 g/dL; Ferritin: 48 ng/mL; Pelvic pain, worst in the past week (0 to 10): 0; PHQ-9: 4; GAD-7: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.4 g/dL (low) at baseline, 12.6 g/dL at this visit **S**
- Ferritin: 6 ng/mL (low) at baseline, 48 ng/mL at this visit **S**
- Pelvic pain, worst in the past week (0 to 10): 4 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 52.4 kg; blood pressure 108/68 |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Pelvic | Cervix small, pale and smooth, with radiation changes and no mass; upper vagina mildly narrowed; rectovaginal examination: parametria soft, without nodularity |
| Legs | No swelling |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the cervix, FIGO 2018 stage IIB** (C53.9). No evidence of disease: complete metabolic response on PET-CT and no tumor on examination. A written survivorship care plan, in Spanish, was given: gynecologic oncology review every three months for two years, then every six months; no routine imaging unless symptoms arise; warning symptoms to report. **S**
   - Gynecologic oncology review next month.
   - Continue the dilator.
   - Report vaginal bleeding, pelvic or back pain, leg swelling, or weight loss without waiting.
2. **Ovarian failure after pelvic radiation** (E89.41). Symptoms controlled; blood pressure normal; no clot symptoms. **S**
   - Continue estradiol and progesterone.
3. **Iron deficiency anemia** (D50.0). Resolved: hemoglobin 12.6 g/dL and ferritin 48 ng/mL now that the bleeding has stopped. **S**
   - Stop ferrous sulfate.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Up to date | A week ago: complete metabolic response |
| Examination | Pelvic, speculum and rectovaginal examination | At diagnosis; every three to six months for two years after treatment | Completed today | No tumor; parametria soft; upper vagina mildly narrowed |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 12.6 g/dL |
| Laboratory | Ferritin | At the end of the iron course | Completed today | 48 ng/mL; iron stopped |
| Examination | Treatment side effects (bowel, bladder, skin, nausea, hearing, nerve symptoms) | At each visit | Completed today | No late bowel or bladder effects; no hearing loss or neuropathy |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 0 of 10 |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Completed today | PHQ-9 4 (item 9 scored 0), GAD-7 4 |
| Self-management | Vaginal dilator use | Starting two to four weeks after radiation, three times a week | Completed today | Three times a week; intercourse comfortable |
| Medication safety | Hormone therapy safety (blood pressure, clot symptoms) and symptom control | At the start and every visit | Completed today | Blood pressure 108/68; no clot symptoms; symptoms controlled |
| Referral | Survivorship care plan and gynecologic oncology follow-up | From the end of treatment | Completed today | Written plan in Spanish given; gynecologic oncology next month |
| Referral | Oncology social worker and spiritual care | Through treatment and survivorship | Completed today | Monthly social work visits |

## Goal progress

- Diagnosis and stage explained to her directly, in Spanish, with time for questions, before any treatment decision. Outcome by 2026-03-02: Diagnosis given to her in person at the second visit and the stage at the third; she made the treatment and fertility decisions herself. **S**
- Hemoglobin 10 g/dL or more before radiation begins. Outcome by 2026-03-02: Hemoglobin 10.2 g/dL. **S**
- Chemoradiation and brachytherapy completed within eight weeks. Outcome by 2026-05-18: Completed in eight weeks, with five cisplatin doses. **S**
- No evidence of disease on PET-CT and examination three months after treatment. Outcome by 2026-08-17: Complete metabolic response; examination without tumor. **S**
- PHQ-9 below 5 by six months. Outcome by 2026-08-17: PHQ-9 4. **S**

## Medication changes

- Stopped: Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027), National Comprehensive Cancer Network
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023), American Society of Clinical Oncology (Journal of Clinical Oncology)
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge

## Follow-up

- Gynecologic oncology review next month. Preventive visit in about a month. **S**
- Next scheduled visit 2026-09-21: periodic adult preventive visit after cancer treatment. **S**
